Amiodarone to prevent arterial fibrillation

Excerpt

The results of this study demonstrate that amiodarone is twice as effective in preventing recurrences of arterial fibrillation (AF) when compared to sotalol and propafenone. It appears to be well tolerated when given in doses of 200 mg/day for a follow up period of 1 year, and significant thyroid and pulmonary complications only occurred in a very small number of subjects. Adverse events resulting from amiodarone are known to be related to the dose and duration of treatment, and so long-term follow-up data (5-10 years) will be important, since AF has a relatively low absolute mortality. Larger studies are needed to show whether amiodarone therapy has any effect on mortality; this was not a primary outcome variable in this study. The authors conclude that amiodarone should therefore be used as primary therapy in AF since it is well tolerated and effective, rather than being reserved for resistant cases because of concerns over its long-term side effects. Obviously the population studied were not critically ill patients, and so these benefits may not translate into the intensive care unit (ICU). AF is a frequent dysrhythmia seen in the ICU, which is usually terminated by treatment of the underlying pathology (e.g. electrolyte imbalance, sepsis, hypovolaemia etc). However, antiarrhythmic agents are often employed in the short term to get control of the situation, and amiodarone certainly appear to be efficacious in restoring sinus rhythm in the critically ill. The results of this study may mean that amiodarone is also an effective agent at preventing recurrences of AF in the critically ill, once the underlying pathology has been stabilised. …